Preliminary results of COVID-19 vaccination among Taiwanese pregnant women: A single-center, prospective,...

To evaluate the impacts of messenger RNA coronavirus disease 2019 (COVID-19) vaccines in Taiwanese pregnant women in terms of obstetrical and neonatal outcomes.

The authors prospectively followed up 450 pregnant women receiving vaccination at a single center. Patients recorded prespecified adverse reactions via a mobile application up to 30 days after the first and second doses. Obstetrical and neonatal outcomes were compared with those of pregnant women, during the same period, who did not undergo vaccination.

Among the 387 women who received the first dose and were followed up for 30 days, injection site pain, fatigue, injection site swelling, muscle ache, and headache were the most prevalent side effects. There were 4.7-, 5.7-, 7.1-, and 9.3-fold increases in fatigue, injection site swelling, muscle ache, and headache, respectively, among the 231 women who received the second dose. Most of the side effects resolved by 14 days and all resolved by 30 days after each doses. There were no significant differences (P > 0.05) in obstetrical and neonatal morbidity or mortality between the vaccinated and unvaccinated cohorts.

No serious adverse reactions were noted among pregnant women receiving messenger RNA vaccinations with comparable obstetrical and neonatal outcomes to unvaccinated pregnant women.